Literature DB >> 7820611

Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum.

S D Glick1, M E Kuehne, J Raucci, T E Wilson, D Larson, R W Keller, J N Carlson.   

Abstract

Ibogaine, a naturally occurring alkaloid, has been claimed to be effective in treating addiction to opioid and stimulant drugs and has been reported to decrease morphine and cocaine self-administration in rats. The present study sought to determine if other iboga alkaloids, as well as the chemically related harmala alkaloid harmaline, would also reduce the intravenous self-administration of morphine and cocaine in rats. Because both ibogaine and harmaline induce tremors, an effect that may be causally related to neurotoxicity in the cerebellar vermis, the temorigenic activities of the other iboga alkaloids were assessed. Lastly, in view of the involvement of the dopaminergic mesolimbic system in the actions of drugs of abuse, the effects of some of the iboga alkaloids on extracellular levels of dopamine and its metabolites in the nucleus accumbens and striatum were determined. All of the tested alkaloids (i.e., ibogaine, tabernanthine, R- and S-coronaridine, R- and S-ibogamine, desethylcoronaridine, and harmaline) dose-dependently (2.5-80 mg/kg) decreased morphine and cocaine intake in the hour after treatment; decreases in morphine and cocaine intake intake were also apparent the day after administration of some but not all of these alkaloids (i.e., ibogaine, tabernanthine, desethylcoronaridine, and the R-isomers of coronaridine and ibogamine). In some rats, there were persistent decreases in morphine or cocaine intake for several days after a single injection or after two or three weekly injections of one or another of these alkaloids; R-ibogamine produced such effects more consistently than any of the other alkaloids.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7820611     DOI: 10.1016/0006-8993(94)90948-2

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  29 in total

1.  In vitro activities of iboga alkaloid congeners coronaridine and 18-methoxycoronaridine against Leishmania amazonensis.

Authors:  Jan Carlo Delorenzi; Leonardo Freire-de-Lima; Cerli R Gattass; Deise de Andrade Costa; Liwen He; Martin E Kuehne; Elvira M B Saraiva
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

Review 2.  Complementary alternative medicine and nuclear medicine.

Authors:  Ursula Werneke; V Ralph McCready
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-01-14       Impact factor: 9.236

Review 3.  Novel pharmacotherapeutic treatments for cocaine addiction.

Authors:  Daryl Shorter; Thomas R Kosten
Journal:  BMC Med       Date:  2011-11-03       Impact factor: 8.775

Review 4.  Kappa opioids as potential treatments for stimulant dependence.

Authors:  Thomas E Prisinzano; Kevin Tidgewell; Wayne W Harding
Journal:  AAPS J       Date:  2005-10-19       Impact factor: 4.009

Review 5.  Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years.

Authors:  Rafael G Dos Santos; Flávia L Osório; José Alexandre S Crippa; Jordi Riba; Antônio W Zuardi; Jaime E C Hallak
Journal:  Ther Adv Psychopharmacol       Date:  2016-03-18

6.  Noribogaine, but not 18-MC, exhibits similar actions as ibogaine on GDNF expression and ethanol self-administration.

Authors:  Sebastien Carnicella; Dao-Yao He; Quinn V Yowell; Stanley D Glick; Dorit Ron
Journal:  Addict Biol       Date:  2010-10       Impact factor: 4.280

7.  Psychedelics re-engineered for potential use in the clinic.

Authors:  Gabriela Manzano-Nieves; Conor Liston
Journal:  Nature       Date:  2021-01       Impact factor: 49.962

8.  Antileishmanial activity of an indole alkaloid from Peschiera australis.

Authors:  J C Delorenzi; M Attias; C R Gattass; M Andrade; C Rezende; A da Cunha Pinto ; A T Henriques; D C Bou-Habib; E M Saraiva
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

Review 9.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

10.  Pharmacological screen for activities of 12-hydroxyibogamine: a primary metabolite of the indole alkaloid ibogaine.

Authors:  J K Staley; Q Ouyang; J Pablo; W L Hearn; D D Flynn; R B Rothman; K C Rice; D C Mash
Journal:  Psychopharmacology (Berl)       Date:  1996-09       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.